Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease.

[1]  Wen-Chung Yu,et al.  Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation. , 2016, Journal of the American College of Cardiology.

[2]  R. Schiffmann,et al.  Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice , 2015, Journal of Inherited Metabolic Disease.

[3]  Richard B. Thompson,et al.  Gender‐specific plasma proteomic biomarkers in patients with Anderson–Fabry disease , 2015, European journal of heart failure.

[4]  C. Wanner,et al.  Fabry disease and the heart. , 2015, Best practice & research. Clinical endocrinology & metabolism.

[5]  M. Beer,et al.  Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. , 2014, The American journal of cardiology.

[6]  S. Chiou,et al.  The generation of induced pluripotent stem cells for macular degeneration as a drug screening platform: identification of curcumin as a protective agent for retinal pigment epithelial cells against oxidative stress , 2014, Front. Aging Neurosci..

[7]  Wen-Chung Yu,et al.  Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset fabry mutation (IVS4 + 919G > A) , 2014, Orphanet Journal of Rare Diseases.

[8]  J. Deleuze,et al.  Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease , 2014, Journal of Inherited Metabolic Disease.

[9]  R. Boot,et al.  Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. , 2014, Biochimica et biophysica acta.

[10]  Y. Eto,et al.  Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp). , 2013, Molecular genetics and metabolism.

[11]  M. A. Mostajo-Radji,et al.  How induced pluripotent stem cells are redefining personalized medicine. , 2013, Gene.

[12]  Euan A Ashley,et al.  Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.

[13]  H. Calkins,et al.  Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs , 2012, Nature.

[14]  Sean P. Palecek,et al.  Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions , 2012, Nature Protocols.

[15]  Y. Chien,et al.  Fabry Disease: Incidence of the Common Later-Onset α-Galactosidase A IVS4+919G→A Mutation in Taiwanese Newborns—Superiority of DNA-Based to Enzyme-Based Newborn Screening for Common Mutations , 2012, Molecular medicine.

[16]  Yang-Hsin Shih,et al.  Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. , 2012, Biomaterials.

[17]  Y. Chien,et al.  Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. , 2011, Human molecular genetics.

[18]  Hideki Uosaki,et al.  Induction and Enhancement of Cardiac Cell Differentiation from Mouse and Human Induced Pluripotent Stem Cells with Cyclosporin-A , 2011, PloS one.

[19]  R. Brady,et al.  Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders , 2010, Proceedings of the National Academy of Sciences.

[20]  Shing‐Jong Lin,et al.  High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese Population , 2009, Circulation. Cardiovascular genetics.

[21]  M. Beer,et al.  Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment , 2009 .

[22]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[23]  R. Desnick,et al.  High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.

[24]  A. Westerveld,et al.  Characterization of α-galactosidase isoenzymes in normal and fabry human-Chinese hamster somatic cell hybrids , 1977, Human Genetics.

[25]  P. McNulty,et al.  Diabetes mellitus and heart failure. , 2003, Congestive heart failure.

[26]  R. Desnick.  α-Galactosidase A deficiency. Fabry disease , 2001 .

[27]  D. Kelly,et al.  The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). , 1998, International journal of molecular medicine.

[28]  R. Desnick,et al.  Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Scheerer,et al.  Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. , 1981, Clinica chimica acta; international journal of clinical chemistry.